PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov.

APPENDIX 1PATIENT INPUT SUMMARY

No patient group input was received regarding this CDR submission for Onglyza.

Copyright © CADTH 2013.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Cover of Saxagliptin (Onglyza)
Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet].

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...